Success Metrics

Clinical Success Rate
95.5%

Based on 21 completed trials

Completion Rate
95%(21/22)
Active Trials
0(0%)
Results Posted
48%(10 trials)
Terminated
1(4%)

Phase Distribution

Ph phase_1
1
4%
Ph phase_2
10
42%
Ph phase_4
7
29%
Ph phase_3
2
8%
Ph not_applicable
2
8%

Phase Distribution

1

Early Stage

10

Mid Stage

9

Late Stage

Phase Distribution22 total trials
Phase 1Safety & dosage
1(4.5%)
Phase 2Efficacy & side effects
10(45.5%)
Phase 3Large-scale testing
2(9.1%)
Phase 4Post-market surveillance
7(31.8%)
N/ANon-phased studies
2(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

91.3%

21 of 23 finished

Non-Completion Rate

8.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

24

all time

Status Distribution
Completed(21)
Terminated(2)
Other(1)

Detailed Status

Completed21
Withdrawn1
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
24
Active
0
Success Rate
95.5%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (4.5%)
Phase 210 (45.5%)
Phase 32 (9.1%)
Phase 47 (31.8%)
N/A2 (9.1%)

Trials by Status

completed2188%
withdrawn14%
unknown14%
terminated14%

Recent Activity

0 active trials
Showing 5 of 24
completednot_applicable

Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study

NCT01522248
completedphase_4

Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults

NCT01811823
completedphase_3

Flu Vaccine Against Childhood Pneumonia, Bangladesh

NCT01319955
completedphase_2

A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age

NCT01258595
completed

Influenza Vaccine in Premature Infants

NCT00455169
View all 24 trials

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT01522248Not Applicable

Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study

Completed
NCT01811823Phase 4

Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults

Completed
NCT01319955Phase 3

Flu Vaccine Against Childhood Pneumonia, Bangladesh

Completed
NCT01258595Phase 2

A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age

Completed
NCT00455169

Influenza Vaccine in Premature Infants

Completed
NCT00766285Phase 2

High Dose Influenza in Immunosuppressed Subjects

Withdrawn
NCT01427309Phase 4

A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults

Completed
NCT01181323Phase 2

Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women

Completed
NCT01436370Phase 2

TIV and High Dose TIV in Subjects With Rheumatoid Arthritis

Completed
NCT01173211Phase 2

2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women

Completed
NCT00115531Phase 2

Eldery High Dose TIV 2005

Completed
NCT00133523Phase 4

FLU-VACS Comparative Study in Adults

Completed
NCT00170547Phase 2

Comparison of Delivery Routes of Flu Vaccine in Adults

Completed
NCT00307177Phase 2

Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma

Completed
NCT01812980Phase 4

Immunogenicity and Safety of Trivalent Influenza Vaccine in Non-pregnant HIV-infected Women

Completed
NCT00570037Not Applicable

Feasibility of Cocooning Immunization Strategy With Influenza Vaccine

Completed
NCT01164553Phase 1

Comparison of Flu Vaccine Doses in Children

Completed
NCT00943202Phase 2

Sanofi Pasteur, TIV + H1N1, Pediatric Population

Completed
NCT00976027Phase 3

Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older

Terminated
NCT00943878Phase 2

Sanofi H1N1 + TIV - Adults and Elderly

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
24